Certificate of Mailing: Date of Deposit: November 17, 1999

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231.

Colleen Coyne

Printed name of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Denise Faustman

Art Unit:

1648

Serial No.

08/925,627

Examiner:

L. Scheiner

Filed

September 9, 1997

Title

METHODS FOR INHIBITING REJECTION OF TRANSPLANTED

TISSUE

Assistant Commissioner of Patents and Trademarks Washington, DC 20231

PETITION FOR EXTENSION OF TIME

NOV 2 6 1999

Pursuant to 37 C.F.R. §1.136, applicants hereby petition that the period for replying 1800/2900 the Examiner's Action mailed May 17, 1999, be extended for three months to and including November 17, 1999.

Enclosed is a check for \$435.00 for the required fee. If there are any other charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Reg. No. 30,162

Clark & Elbing LLP 176 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

\Ceserver\documents\00786\036xxx\00786.036005 Petition for Extension of Time.wpd





ATCC TIB 92 10-3.6.2 (Anti I-At [t, r, f, or s])

Current medium for propagation: Dulbecco's modified Eagle's medium with 4.5 g/L glucose, 90%; fetal bovine serum, 10%. Additional Information: This hybridoma secretes a monoclonal IgG_{2a} antibody which recognizes I-A^k (k, r, f, or s haplotype). The hybridoma was formed by fusing spleen cells from CWB mice immunized with C3H spleen cells with the NS-1 myeloma. Reference: Curr. Top. Microbiol. Immunol. 81: 115-129, 1978. Originator: L. Herzenberg, Stanford University School of Medicine, Stanford, CA. Note: This material is available under the conditions that you will not use it for commercial purposes or distribute it to third parties. Please see pages xv and xvi for the form required.

Price Code: J

ATCC TIB 93 10-2.16 (Anti I-Ak [k, r, f, or s])

Current medium for propagation: Dulbecco's modified Eagle's medium with 4.5 g/L glucose, 90%; fetal bovine serum, 10%. Additional Information: This hybridoma secretes a monoclonal IgG_{2b} antibody which recognizes I-A^k (k, r, f or s haplotype). This hybridoma was formed by fusing the spleen cells from CWB mice immunized with C3H spleen cells with the NS-1 myeloma. Reference: Curr. Top. Microbiol. Immunol. 81: 115-129, 1978. Originator: L. Herzenberg, Stanford University School of Medicine, Stanford, CA. Note: This material is available under the conditions that you will not use it for commercial purposes or distribute it to third parties. Please see pages xv and xvi for the form required.

Price Code: J

ATCC TIB 94 11-5.2.1.9 (Anti I-Ah)

Current medium for propagation: Dulbecco's modified Eagle's medium with 4.5 g/L glucose, 90%; fetal bovine serum, 10%. Additional Information: This hybridoma secretes a monoclonal IgG_{2b} antibody which recognizes I-A^k. This hybridoma was formed by fusing spleen cells from BALB/c mice immunized with CKB cells with the NS-1 myeloma. Reference: Curr. Top. Microbiol. Immunol. 81: 115-129, 1978. Originator: L. Herzenberg, Stanford University School of Medicine, Stanford, CA. Note: This material is available under the conditions that you will not use it for commercial purposes or distribute it to third parties. Please see pages xv and xvi for the form required.

Price Code: J

ATCC TIB 95 11-4.1 (Anti H-2 Kk [k, q, r, or p haplotype])

Current medium for propagation: Dulbecco's modified Eagle's medium with 4.5 g/L glucose, 90%; fetal bovine serum, 10%. Additional Information: This hybridoma secretes an IgG_{2a} antibody which recognizes H-2 K^k (k, q, r, or p haplotype). This hybridoma was formed by fusing spleen cells from BALB/c mice immunized with CKB cells with the NS-1 myeloma. Reference: Curr. Top. Microbiol. Immunol. 81: 115-129, 1978. Originator: L. Herzenberg, Stanford University School of Medicine, Stanford, CA. Note: This material is available under the conditions that you will not use it for commercial purposes or distribute it to third parties. Please see pages xv and xvi for the form required.

Price Code: J

ATCC TIB 96 Ig(5b)6.3 (formerly 11-6.3.1) (Anti Ig-5b allotype on IgD)

Current medium for propagation: Dulbecco's modified Eagle's medium with 4.5 g/L glucose, 90%; fetal bovine serum, 10%. Additional Information: This hybridoma secretes a monoclonal IgG₁ antibody which recognizes Ig-5b (IgD of b allotype). The hybridoma was formed by fusing the spleen cells from BALB/c mice immunized with CKB cells with the NS-1 myeloma. Reference: Curr. Top. Microbiol. Immunol. 81: 115-129, 1978. Originator: L. Herzenberg, Stanford University School of Medicine, Stanford, CA. Note: This material is available under the conditions that you will not use it for commercial purposes or distribute it to third parties. Please see pages xv and xvi for the form required.

Price Code: J

ATCC TIB 98 RDP 45/20 (Anti Ig-1b)

Current medium for propagation: Dulbecco's modified Eagle's medium with 4.5 g/L glucose, 90%; fetal bovine serum, 10%. Additional Information: This hybridoma secretes an IgM antibody which is specific for the mouse Ig-1b allotypic marker antigen. It was formed by the fusion of spleen cells from BALB/c mice immunized with CBPC-101 myeloma protein [IgG_{2a} (1g-1b)] with the BALB/c myeloma MPC-11. Reference: Curr. Top. Microbiol. Immunol. 81: 37-39, 1978. Originator: W.C. Raschke, La Jolla Cancer Research Foundation, La Jolla, CA.

ATCC TIB 99 HO-13-4 (Anti Thy 1.2)

Current medium for propagation: Dulbecco's modified Eagle's medium with 4.5 g/L glucose, 90%; fetal bovine serum, 10%. Additional Information: This hybridoma secretes a monoclonal IgM antibody specific for Thy-1.2 antigen. This specificity was demonstrated by lysis of A/J (Thy-1.2) thymocytes at plateau titers of 2 × 10⁴ to 2 × 10⁶. Slight cross-reactivity was shown on A/Thy-1.1 thymocytes at dilutions about 5 × 10⁵ fold lower than the dilutions required for similar levels of lysis of Thy-1.2 thymocytes. Furthermore, this antibody lyses only 60-70% of lymph node cells suggesting complement-dependent cytotoxicity for mature T cells and not B cells. Treatment of peripheral lymphocyte populations with monoclonal antibody plus complement eliminated effector cytotoxic T-lymphocytes, their precursors, and the mitogenic response to ConA, but did not affect the response to LPS. Purified HO-13-4 antibody coupled to Sepharose 6MB has been used to separate viable T and B cells. HO-13-4 was formed by the fusion of cells of the mouse myeloma line P3X63-Ag8 with spleen cells from AKR/J mice immunized with C3H thymocytes. Reference: J. Immunol. 122: 2491-2497, 1979. Originator: A. Marshak-Rothstein, Massachusetts Institute of Technology, Cambridge, MA. Note: This material is available under the conditions that you will not use it for commercial purposes or distribute it to third parties. Please see pages xv and xvi for the form required.

Price Code: J